
Scott B. Crofton
PartnerScott B. Crofton
PartnerScott Crofton is a partner in Sullivan & Cromwell’s Mergers and Acquisitions Group. He advises public and private companies as well as private equity firms on noteworthy domestic and cross-border transactions, alliances and joint ventures, and special situations and structures across a variety of industries, including the industrials and healthcare sectors. He also counsels clients on corporate governance matters, defensive measures and other strategic matters. Scott has been recognized as a “Rising Star for Corporate, M&A and Private Equity” by Euromoney in 2021, a “Rising Star in M&A” by IFLR1000 from 2018-2020 and named a winner of M&A Advisor’s “Emerging Leader Award” in 2016.
SELECTED REPRESENTATIONS
Industrials Transactions. Mr. Crofton’s expertise includes a broad range of complex high-profile industrials, chemicals, manufacturing, and oil & gas transactions, including advising on the following:
- Ally Financial in the $4.2 billion sale of its automotive lending operations in Europe and Latin America, as well as its share in a joint venture in China, to a subsidiary of General Motors
- GAF, a Standard Industries company, in its acquisition of FT Synthetics (Canada)
- Genesis Robotics in its strategic, controlling investment from Koch Chemical Technology Group, a unit of Koch Industries
- Stockholders of International Specialty Products in connection with its $3.2 billion sale to Ashland
- K+S AG (Germany) in its $3.2 billion sale of its Americas salt business to Stone Canyon Industries Holdings, Mark Demetree and affiliates
- L3Harris (formerly Harris Corporation) in its approximately $1.96 billion acquisition of Viasat’s Tactical Data Links product line; $1.05 billion sale of its Military Training business to CAE (Canada); $35 billion merger of equals between Harris Corporation and L3 Technologies; $4.6 billion acquisition of Exelis; and $350 million sale of its Night Vision business to Elbit Systems of America
- Navistar International in its $3.7 billion acquisition by TRATON (formerly Volkswagen Truck & Bus) (Germany) and strategic alliance with TRATON including an equity investment in Navistar by TRATON and framework agreements for strategic technology and supply collaboration and a procurement joint venture
- Outerstuff in connection with its close on an investment by private equity funds affiliated with The Blackstone Group, resulting in a 50/50 economics and governance structure
- Standard Industries Holdings in its $7 billion acquisition of W. R. Grace & Co., acquisition of Quest Construction Products and $2.1 billion acquisition of Braas Monier Building Group (Luxembourg/Germany)
- Standard Investments and Standard Industries, as the largest stockholders in GCP Applied Technologies, in connection with Saint-Gobain’s (France) $2.3 billion acquisition of all outstanding shares of GCP
- Tenaris S.A. (Luxembourg) in its $1.2 billion acquisition of IPSCO Tubulars from PAO TMK (Russia) and $335 million sale of Republic Conduit to Nucor
- UIL Holdings in its $4.6 billion acquisition by Iberdrola (Spain)
- United Rentals in its successful topping bid to acquire Neff Corporation for $1.3 billion
- Watlow in its sale to Tinicum L.P.
- The Weir Group (U.K.) in its $405 million sale of its Oil & Gas division to Caterpillar and $1.3 billion acquisition of ESCO
- AbbVie in its $55 billion proposed acquisition of Shire (U.K.) (later terminated)
- Apple Tree Partners as the majority shareholder in Syntimmune, in Syntimmune’s acquisition by Alexion Pharmaceuticals for up to $1.2 billion
- Biohaven Pharmaceuticals in its $11.6 billion acquisition by Pfizer, acquisition of Channel Biosciences, a subsidiary of Knopp Biosciences, and its Kv7 channel targeting platform; $1.24 billion strategic commercialization arrangement with Pfizer for rimegepant in markets outside of the U.S., as well as rights to zavegepant; and $100 million sale of tiered, sales-based participation rights on future global net sales of products containing rimegepant (BHV-3000) or BHV-3500 and $50 million sale of common shares to Royalty Pharma
- Blackstone in connection with Precision Medicine Group’s major investment and recapitalization
- INC Research in its $7.4 billion merger of equals with inVentiv Health, creating Syneos Health
- Optimer Pharmaceuticals in its $800 million acquisition by Cubist Pharmaceuticals
- Stryker Corporation in its $2.8 billion acquisition of Sage Products from Madison Dearborn Partners
- Terumo Corporation (Japan) in its $1.1 billion acquisition of certain vascular closure product lines and access technologies from Abbott Laboratories and St. Jude Medical
- Abrams Capital Management in the sale of Netrality Data Centers to Macquarie Infrastructure Partners IV
- AT&T in its $67 billion acquisition of DIRECTV
- Benefitfocus in its $570 million acquisition by Voya Financial
- Bright House Networks in its three-way combination with Charter Communications and Time Warner Cable, to create an $80 billion cable company
- Collective Brands in its $2 billion sale and post-closing division of business operations to a consortium including Wolverine Worldwide, Blum Capital Partners and Golden Gate Capital
- DISH Network in its agreement with T-Mobile, Sprint and the U.S. Department of Justice under which DISH acquired Sprint’s prepaid wireless business and entered the U.S. wireless market as the fourth nationwide facilities-based provider; acquisitions of Republic Wireless and Ting Mobile; acquisition of certain hardware, software and over-the-top assets from EchoStar in exchange for DISH’s interests in Hughes Retail Group; and $10 billion unsolicited offer for Clearwire Corporation (later terminated)
- Dynegy in its proposed take-private transactions with The Blackstone Group and Icahn Enterprises
- Eastman Kodak Company in asset sale transactions in connection with its emergence from Chapter 11 bankruptcy proceedings
- HelloFresh (Germany) in its $277 million acquisition of Factor75
- Oasis Systems in its combination with ERC, a portfolio company of Brightstar Capital Partners
- Unisys in its $1.2 billion sale of its U.S. Federal business to Science Applications International